Fig. 1 (abstract P129).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part OnePercent increase in clones in mCRPC patients retreated with sip-T (P10-1) compared with patients receiving a late booster treatment (STRIDE)Back to article page